Sanofi SA to Discuss Collaboration With Translate Bio to Develop a Novel mRNA Vaccine Candidate Against COVID-19 Conference Call Transcript
Ladies and gentlemen, thank you for standing by. Welcome to the Sanofi conference call on the expansion of their collaboration with Translate Bio to develop a COVID-19 vaccine.
I would now like to turn the call over to Felix Lauscher from Sanofi Investor Relations. Please go ahead, sir.
Thank you. Good morning, and good afternoon to everyone on the call. We hope everyone is well. Thank you for joining us to review the details of this important new initiative against the coronavirus. As usual, you can find the slides to this call on the Investors page of our website at sanofi.com.
Moving to Slide 2. I would like to remind you that information presented in this call contain forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. I refer you to our Form 20-F document on file with the SEC and also our Document de Référence for a description of these risk factors.
With that, please
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
